The JuLi Registry seeks to fill some of the gaps associated with the clinical application of
CBD (cannabidiol) and other cannabinoid formulations including THC and others. It will also
serve as a platform for discovery, whereby observations of patient symptoms, specific
cannabis formulations, delivery methods and clinical outcomes, become the source of more
in-depth research projects.
The JuLi Registry is a prospective observational Registry documenting utility and patient
experience for patients seeking to use therapeutic cannabis and hemp-based products as a
means of symptom relief and management related to various diseases.
Targeted symptoms and conditions include:
Chronic Pain
Neuropathy
Sleeplessness
Poor Appetite
Nausea
Anxiety
Menopausal symptoms
Data to be recorded includes:
Basic demographics of patients using cannabis-based or hemp-based products
Disease diagnoses and symptoms for which patients are seeking management
Cannabinoid formulation, chemical composition, amount (in milligrams), dose and
utilization
Patient Reported Outcomes (PRO) using, where possible, validated measures of sleep,
pain, appetite, etc.
Physician and patient utilization of these data to manage prescription medication
recommendations and usage, including discontinuation of opiates or reduction in use of
opiates after initiation of cannabis- or hemp-based products
Overall impact on clinical or patient treatment plan
The purpose of this Registry is to provide a platform for physicians and patients to
collaborate on hemp and cannabis research and advance the understanding of the application of
cannabinoids for symptom relief associated with various medical conditions.
Patients greater than or equal to 21 years of age seeking to use CBD or other cannabis-based
formulations, where legal, will be invited to participate.
Data collected in the normal course of a patient's visit and follow up are entered. This is
an observational study; no specific patient interventions are required. Patients must have
requested a cannabis-based medicament from their provider. Or be otherwise deemed eligible
per the research protocol and choose to participate in a self-directed manner.
Data will be collected at various time points, including:
At the time patients first request cannabis or hemp based products
At various recommended and voluntary time points, collected via PRO surveys
Daily or whenever they are using their products via the use of a study app
When patients return to their providers during the course of normal clinical care
All patients must sign an electronic informed consent form prior to their prospective data
being entered into the Registry.
All demographic, diagnostic, hemp/cannabis formulation and follow up data will be entered by
patients. Consented patients will record compliance with recommendations, usage and symptom
relief. They will be asked to take symptom specific surveys.